Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-06-13
2006-06-13
Schwadron, Ronald B (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C530S826000, C530S327000, C530S324000, C530S325000, C514S002600, C424S186100, C424S204100, C424S230100, C424S192100, C424S193100, C424S196110, C424S199100, C435S975000
Reexamination Certificate
active
07060283
ABSTRACT:
Epstein-Barr virus (EBV) specific polypeptides consisting of a series of one to 1000 peptide units selected from the group consisting of peptide units Φ, Γ, Δ and Ω, wherein Φ is 25 amino acids or less and has the formula (αETFTETWNRFITHTEβ) (SEQ ID NO:1), Γ is 25 amino acids or less and has the formula (αGMLEASEGLDGWIHQβ) (SEQ ID NO:2), Δ is 25 amino acids or less and has the formula (αHQQGGWSTLIEDNIβ) (SEQ ID NO:3), Ω is 25 amino acids or less and has the formula (αKQKHPKKVKQAFNPLβ) (SEQ ID NO:4), α and β are each independently from 0 to 5 naturally occurring amino acids, and the polypeptide is capable of binding antibody in a specimen from an individual with Epstein-Barr virus (EBV)-associated disease are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.
REFERENCES:
patent: 3654090 (1972-04-01), Schuurs et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 4016043 (1977-04-01), Schuurs et al.
patent: 4172124 (1979-10-01), Koprowski et al.
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 3654090 (1982-07-01), Schuurs et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4879213 (1989-11-01), Fox et al.
patent: 017254 (1986-03-01), None
patent: 0 280 813 (1988-09-01), None
patent: 9108224 (1991-06-01), None
patent: WO 94/06470 (1994-03-01), None
patent: 9408597 (1994-04-01), None
patent: WO 94/08597 (1994-04-01), None
Jackman et al., Vaccine, 17:660-668, 1999.
Burton et al., “A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals” Proc. Natl. Acad. Sci. USA vol. 88: 10134-10137 (Nov. 1991).
Curtiss, L.K. et al., “Localization of Two Epitopes of Apolipoprotein A-I That are Exposed on Human High Density Lipoproteins Using Monoclonal Antibodies and Synthetic Peptides”, J. Biol. Chem., vol. 263, No. 27: 13779-13785 (Sep. 1988).
Diener et al., “Specific Immunosuppression by Immunotoxins Containing Daunomycin” Science vol. 231: 148-150 (Jan. 1986).
Douillard, J.Y. and Hoffman, “Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors” T. Hybridoma 5 Supp 1: S139-S149 (Jul. 1986).
Eisenlohr et al., “Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes” J. Exp Med. vol. 175: 481-487 (Feb. 1992).
Greiner et al., “Recombinant Interferon Enhances Monoclonal Antibody-Targeting of Carcinoma Lesions in Vivo” Science vol. 235, No. 4791: 895-898 (Feb. 1987).
Henle et al, “Epstein-Barr Virus Diagnostic Tests in Infectious Mononucleosis” Human Pathology vol. 5, No. 5: 551-565 (Sep. 1974).
Henle et al., “Demonstration of Two Distinct Components in the Early Antigen Complex of Epstein-Barr Virus-Infected Cells” Int. J. Cancer vol. 8, No. 3: 272-282 (Nov. 1971).
Herlyn et al., “Anti-Idiotypic Antibodies Bear the Internal Image of a Human Tumor Antigen” Science vol. 232, No. 4746: 100-102 (Apr. 1986).
Hinuma, Y. et al., “Immunofluorescence and Herpes-Type Virus Particles in the P3HR-1 Burkitt Lymphoma Cell Line” J. Virol. vol. 1, No. 5: 1045-1051 (Oct. 1967).
Jemmerson, “Effects of Conformation, Amino Acid Sequence, and Carrier Coupling on the Immunological Recognition of Peptide and Protein Antigens” Effects on Immunological Recognition of Peptides in Medicine And Biology, Edited by Zegers, Boiersma, Classen, CRC Press Inc., New York Chapter 16, 213-225 (1995).
Köhler and Milstein, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity” Nature: vol. 256, No. 5517 495-497 (Aug. 1975).
Lenard, J. et al., “Use of Hydrogen Fluoride in Merrifield Solid-Phase Peptide Synthesis” J. Am. Chem. Soc. vol. 89, No. 1: 181-182 (Jan. 1967).
Luka et al., “A Sensitive Enzyme-Linked Immunosorbent Assay (Elisa) Against the Major EBV-Associated Antigens. I. Correlation between Elisa and Immunofluorescence Titers Using Purified Antigens” J. Immunol. Methods 67: 145-156 (1984).
Merrifield, “Solid Peptide Synthesis. I. The Synthesis of a Tetrapeptide”, J. Am. Chem. Soc. 85: 2149-2154 (Jul. 1963).
Oi et al., “Chimeric Antibodies”, Bio Techniques vol. 4, No. 3: 214-221 (May/Jun. 1986).
Pearson et al., “Application of Epstein-Barr Virus (EBV) Serology to the Diagnosis of North American Nasopharyngeal Carcinoma” Cancer 51: 260-268 (Jan. 1983).
Smith et al., “Antibodies to an Epstein-Barr Virus Nuclear Antigen Synthetic Peptide in Infectious Mononucleosis” Am. J. Clin. Pathology vol. 92 No. 4: 447-451 (Oct. 1989).
Spira et al., “The Identification of Monoclonal Class Switch Variants by Sib Selection and an Elisa Assay” J. Immunol. Methods 74: 307-315 (1984).
Steplewski et al., “Isolation and Characterization of Anti-Monosialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants” Proc. Natl. Acad. Sci., USA, vol. 82: 8653-8657 (Dec. 1985).
Stewart and Young, “Laboratory Techniques in Solid Phase Peptide Synthesis” Solid Phase Peptides Synthesis (W. H. Freeman & Company, San Francisco, Chapter 2 pp. 27-64 (1969).
Sun et al., “Chimeric Antibodies with 17-1A-Derived Variable and Human Constant Regions” Hybridoma, vol. 5 Supplement 1: S17-S20 (1986).
Sutcliffe et al., “Antibodies That React With Predetermined Sites on Proteins” Science vol. 219, No. 4585: 660-666 (Feb. 1983).
Tainer et al, “The Reactivity of Anti-Peptide Antibodies is a Function of the Atomic Mobility of Sites in a Protein” Nature 312: 127-134 (Nov. 1984).
Wolff et al, “The Use of Monoclonal Anti-Thy1IgG1for the Targeting of Liposomes to AKR-A Cells in Vitro and in Vivo” Biochemica et Biophysica Acta, 802: 259-273 (1984).
Young “Epstein-Barr Virus” Encyclopedia of Virology, vol. 1, Edited by Webster and Granoff, Academic Press, 404-416 (1994).
Baer, et al.,Nature310:207, 1984, DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
Rhodes, et al.,J. Immunol.,143:211, 1985, Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen.
Dillner,J. Proc. Natl. Acad. Sci, U.S.A.81:652, 184, Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen.
Lerner, et al.,Nature,299:592, 1982, Tapping the immunological repertoire to produce antibodies of predetermined specificity.
Pothen, et al.,Int. J. Cancer,49:656, 1991, Human T-Cell Recognition of Epstein-Barr Virus-Induced Replication Antigen Complexes.
Ulaeto, et al.,Europ. J. Immunol,18:1689, 1986 In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD$+T cell clones specific for the major envelope glycoprotein gp340*.
Pothen, et al.,Int. J. Cancer,53:199 (1993), Identification of T- and B-Cell Epitopes Associated with a Restricted Component of the Epstein-Barr Virus-Induced Early Antigen Complex.
Ortho Diagnostic Systems, Inc., ORTHO* Epstein-Barr Virus EA(D+R)-IgG Antibody Elisa Test, Product Code 520025, Draft revised Aug. 20, 1993.
Gull Laboratories, EBV-EA Test, Product No. EA100 1988.
Fox, et al., Synthetic Peptide Derived from the Epstein-Barr Virus Encoded Early Diffuse Antigen (EA-D) Reactive with Human Antibodies, J. of Clinical Laboratory Analysis, 1:140-145 (1987).
G.R. Pearson, et al., “Identification of an Epstein-Barr Virus early gene encoding a second component of the restricted early antigen complex”, Virology, vol. 160, Jun. 1987, pp. 151-161.
T.A. Waldmann, “Monoclonal Antibodies in diagnosis and therapy”, Science, vol. 252, Jun. 21, 1991, pp. 1657-1662.
Parks D. Elliot
Pearson Gary R.
Smith Richard S.
Varghese Susan Pothen
Georgetown Univeristy
Ortho Diagnostic Systems Inc.
Schwadron Ronald B
Woodcock & Washburn LLP
LandOfFree
Immunoreactive peptides from Epstein-Barr virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoreactive peptides from Epstein-Barr virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoreactive peptides from Epstein-Barr virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3698030